iPath Optimized Currency Carry ETN ICI
36.05 USD 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
36.05 Day range 36.05
36.05 52-week range 37.90
- Volume
- 11
- Open
- 36.05
- Previous close
- 36.05
- Day's range
- 36.05 – 36.05
- 52-week range
- 36.05 – 37.90
No chart data for this range yet.
News
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting 
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI 
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors 
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting 
Tempus AI Taps Growing ICI Market With New xM Assay 
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment 
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting 
The growth rate of eight basic industries of the country was 3.6 percent in March. 
General Cable Announces Joint Venture in Oman
Your note
Sign in to keep a note on ICI — it syncs with the Stock Master app.